CovalX and Bruker Daltonics Announce Strategic Collaboration in High Mass MALDI Detection
Summary
Zurich, Switzerland, June 07, 2013 --( This collaboration draws upon CovalX´s experience as a leader in providing novel tools and unique applications for intact protein-protein interaction and macromolecular analysis, and Bruker Daltonics´ cutting-edge life-science systems based on mass spectrometry (MS).Ryan Wenzel, CSO and Director of North American Operations at CovalX, commented: "This collaboration demonstrates CovalX´s commitment to increasing access to our high mass detection technology for all MALDI platforms, and to work with the manufacturers to find a solution for all customers." Currently manufacturing the third generation of high mass detection systems, the HM3, CovalX´s technology is already well recognized as a unique tool for protein-protein interactions analysis, which includes stoichiometry, biotherapeutic aggregation, epitope mapping and immunocomplex characterization; all key applications for the biotech and pharmaceutical industries.The company currently has released its third generation of high mass MALDI detection systems on the market with a range of stabilization chemistries and data analysis software for applications characterizing protein interactions.There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.About CovalXCovalX is the market leader in intact protein complex analysis using high mass MALDI based technology with headquarters in Zürich, Switzerland and a North American subsidiary in Saugus, MA.